Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

2025 Pharma Manufacturing Conference

The North of England continues to be a key player in the life sciences sector, with significant investment driving growth. Home to 21% of the [...]

Go to Top